Vaccitech (NASDAQ:VACC) Stock Rating Reaffirmed by HC Wainwright

Vaccitech (NASDAQ:VACCGet Rating)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Monday. They presently have a $20.00 target price on the stock.

Separately, Morgan Stanley lowered their target price on Vaccitech from $19.00 to $16.00 and set an “overweight” rating for the company in a report on Monday, August 15th.

Vaccitech Stock Performance

Vaccitech stock opened at $2.59 on Monday. Vaccitech has a 1 year low of $2.12 and a 1 year high of $13.49. The firm’s 50-day moving average is $3.01 and its 200-day moving average is $4.03. The company has a market cap of $96.60 million, a P/E ratio of 7.81 and a beta of 0.22.

Insider Activity

In related news, insider Graham Griffiths sold 10,000 shares of Vaccitech stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $7.39, for a total value of $73,900.00. Following the sale, the insider now directly owns 104,209 shares in the company, valued at approximately $770,104.51. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 12,625 shares of company stock valued at $86,578. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of Vaccitech

An institutional investor recently raised its position in Vaccitech stock. M&G Investment Management Ltd. lifted its stake in shares of Vaccitech plc (NASDAQ:VACCGet Rating) by 377.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,197,349 shares of the company’s stock after acquiring an additional 4,108,752 shares during the quarter. M&G Investment Management Ltd. owned about 13.96% of Vaccitech worth $15,592,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.86% of the company’s stock.

Vaccitech Company Profile

(Get Rating)

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.

Featured Stories

Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with's FREE daily email newsletter.